Sepio Capital, LP Gilead Sciences, Inc. Transaction History

Sepio Capital, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 03, 2023	BUY	$62.32 - $89.47 $165,521 - $237,632	2,656 New	2,656 $228,000
Q4 2020 Feb 10, 2021	SELL	$56.65 - $64.55 $209,605 - $238,835	-3,700 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$62.1 - $78.08 $71,725 - $90,182	-1,155 Reduced 23.79%	3,700 $234,000
Q2 2020 Aug 04, 2020	SELL	$72.34 - $84.0 $332,764 - $386,400	-4,600 Reduced 48.65%	4,855 $374,000
Q1 2020 Apr 29, 2020	SELL	$62.63 - $80.22 $90,562 - $115,998	-1,446 Reduced 13.26%	9,455 $707,000
Q4 2019 Feb 06, 2020	SELL	$61.62 - $67.78 $10,352 - $11,387	-168 Reduced 1.52%	10,901 $708,000
Q3 2019 Oct 25, 2019	BUY	$62.51 - $69.0 $308,611 - $340,653	4,937 Added 80.51%	11,069 $707,000
Q2 2019 Aug 08, 2019	SELL	$61.87 - $69.38 $113,345 - $127,104	-1,832 Reduced 23.0%	6,132 $414,000
Q1 2019 Jun 21, 2019	BUY	$62.53 - $70.05 $497,988 - $557,878	7,964 New	7,964 $524,000
Q1 2019 May 14, 2019	SELL	$62.53 - $70.05 $933,010 - $1.05 Million	-14,921 Closed	0 $0
Q4 2018 Feb 13, 2019	BUY	$60.54 - $79.0 $903,317 - $1.18 Million	14,921 New	14,921 $933,000

1,893

1.02B

12M

9.04M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Sepio Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Sepio Capital, LP with notifications on news.